Pharma Pulse: Onshoring the Supply Chain

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• The FDA is taking what Commissioner Marty Makary calls a "bold step" to bring drug manufacturing back to US soil. The agency just launched the PreCheck Pilot Program, a two-phase initiative designed to eliminate regulatory guesswork for domestic facilities. For the first time, manufacturers can get early technical advice and pre-operational reviews before they even file a formal drug application. By streamlining the path for critical medications, the FDA aims to shore up the supply chain and end decades of reliance on overseas production.
• Meanwhile, semaglutide is proving to be a powerful tool for hospital resource management. New exploratory data from the SELECT trial—published in JAMA Cardiology—reveals that Wegovy significantly cuts total hospital admissions and length of stay for patients with heart disease, a massive win for healthcare systems and payers looking to curb the multi-billion-dollar costs associated inpatient care.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.